The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
200
Time averaged percentage change from baseline between Day 60 and Day 180
Time averaged change from baseline in log Lp(a) measured between Day 60 and Day 180, defined as the area under the curve (AUC) between the Day 60 Visit date and the Day 180 Visit date, divided by the duration between the two visit dates.
Time frame: baseline to day 60 and day 180
Difference between DII235 dose 2 and placebo in time-averaged percent change from baseline in Lp(a) measured between Day 60 and Day 360
Time averaged change from baseline in log Lp(a) measured between Day 60 and Day 360, defined as the area under the curve (AUC) between the Day 60 visit date and the Day 360 visit date, divided by the duration between the two visit dates.
Time frame: baseline to day 60 and day 360
Difference between DII235 dose 4 and placebo in time-averaged percent change from baseline in Lp(a) measured between Day 60 and Day 360
Time averaged change from baseline in log Lp(a) measured between Day 60 and Day 360, defined as the area under the curve (AUC) between the Day 60 visit date and the Day 360 visit date, divided by the duration between the two visit dates.
Time frame: baseline to day 60 and day 360
Difference between DII235 dose 1, dose 3 and placebo versus placebo in time-averaged percent change from baseline in Lp(a) measured between Day 60 and Day 360
Time averaged change from baseline in log Lp(a) measured between Day 60 and Day 360, defined as the area under the curve (AUC) between the Day 60 visit date and the Day 360 visit date, divided by the duration between the two visit dates.
Time frame: baseline to day 60 and 360
Difference between DII235 doses versus placebo in time-averaged percent change from baseline in Lp(a) measured between Day 240 and Day 360
Time averaged change from baseline in log Lp(a) measured between Day 240 and Day 360, defined as the area under the curve (AUC) between the Day 240 Visit date and the Day 360 Visit date, divided by the duration between the two visit dates.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Parkway Medical Center
Birmingham, Alabama, United States
RECRUITINGHeart Center Research Llc
Huntsville, Alabama, United States
RECRUITINGCardiology and Medicine Clinic PA
Little Rock, Arkansas, United States
RECRUITINGNational Heart Institute
Beverly Hills, California, United States
RECRUITINGAlliance Clinical
Canoga Park, California, United States
RECRUITINGExcel Medical Clinical Trials LLC
Boca Raton, Florida, United States
RECRUITINGZenith Clinical Research
Hollywood, Florida, United States
RECRUITINGJacksonville Center for Clinical Research
Jacksonville, Florida, United States
RECRUITINGFlourish Res Acq LLC North Miami
Miami, Florida, United States
RECRUITINGInpatient Research Clinical LLC
Miami Lakes, Florida, United States
RECRUITING...and 36 more locations
Time frame: baseline to day 240 and Day 360
Difference between DII235 doses versus placebo with respect to the proportion of participants in achieving Lp(a) < 125 nmol/L at Day 180 and Day 360
Participant's status of achieving Lp(a) \< 125 nmol/L at Day 180 and at Day 360 (Yes, No), without having any defined intercurrent events.
Time frame: Day 180 and Day 360
Difference between DII235 doses versus placebo with respect to the proportion of participants in achieving Lp(a) < 75 nmol/L at Day 180 and Day 360
Participant's status of achieving Lp(a) \< 75 nmol/L at Day 180 and at Day 360 (Yes, No), without having any defined intercurrent events.
Time frame: Day 180 and Day 360